INT220148

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 5.56
Pain Relevance 0.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IGF1, IGFBP3) extracellular region (IGF1, IGFBP3) signal transduction (IGF1)
nucleus (IGFBP3)
Anatomy Link Frequency
plasma 1
liver 1
IGF1 (Homo sapiens)
IGFBP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 17 100.00 Very High Very High Very High
rheumatoid arthritis 79 79.92 Quite High
cva 3 67.84 Quite High
headache 4 63.28 Quite High
Osteoarthritis 11 61.52 Quite High
cytokine 21 59.44 Quite High
Pain 6 54.44 Quite High
agonist 4 36.72 Quite Low
antagonist 2 18.24 Low Low
Inflammation 31 17.56 Low Low
Disease Link Frequency Relevance Heat
Cancer 39 99.92 Very High Very High Very High
Alopecia 3 98.12 Very High Very High Very High
Apoptosis 165 96.64 Very High Very High Very High
Hypoglycemia 32 96.40 Very High Very High Very High
Hypertrophy 9 91.48 High High
Osteoporosis 12 89.76 High High
Colon Cancer 30 89.12 High High
Disease 26 88.88 High High
Anorexia 1 86.12 High High
Growth Problems 107 85.88 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
IGF-1 and IGFBP-3 both promote the differentiation of bone, with systemic levels of IGF-1 and IGFBP-3 positively associated with bone mass density [12].
IGF-1 Binding (associated) of IGFBP-3
1) Confidence 0.36 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2669552 Disease Relevance 0.57 Pain Relevance 0.03
IGF-1 and IGFBP-3 both promote the differentiation of bone, with systemic levels of IGF-1 and IGFBP-3 positively associated with bone mass density [12].
IGF-1 Binding (associated) of IGFBP-3
2) Confidence 0.36 Published 2003 Journal Tob Induc Dis Section Body Doc Link PMC2671651 Disease Relevance 0.57 Pain Relevance 0.03
It is worth noting that IGF-1 usually complexes with IGFBP-3 and ALS that depend on GH level and action.
IGF-1 Binding (complexes) of IGFBP-3
3) Confidence 0.29 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0 Pain Relevance 0
IGF-binding protein-3 (IGFBP-3) is major IGF binding protein and is thought to exert a protective effect through modulation of IGF-I bioactivity as well as through IGF-I independent effects on cell proliferation and apoptosis [36].
IGF-I Binding (modulation) of IGFBP-3 associated with apoptosis
4) Confidence 0.27 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 1.02 Pain Relevance 0.05
IGF-binding protein-3 (IGFBP-3) is major IGF binding protein and is thought to exert a protective effect through modulation of IGF-I bioactivity as well as through IGF-I independent effects on cell proliferation and apoptosis [36].
IGF-I Binding (modulation) of IGF-binding protein-3 associated with apoptosis
5) Confidence 0.27 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2409350 Disease Relevance 1.03 Pain Relevance 0.05
The insulin-like growth factor binding protein-3 (IGFBP-3) is the main carrier protein binding to IGF-I in plasma, thus determining its bioavailability.
IGF-I Binding (binding) of IGFBP-3 in plasma associated with bioavailability
6) Confidence 0.27 Published 2010 Journal Thyroid Res Section Body Doc Link PMC2858102 Disease Relevance 0.09 Pain Relevance 0.05
These data demonstrated that large amount of rhIGF1 are needed, when administered complexed with IGFBP-3, to obtain the growth response comparable to rhIGF1 alone.
rhIGF1 Binding (complexed) of IGFBP-3
7) Confidence 0.20 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724186 Disease Relevance 0.06 Pain Relevance 0
A complex of IGF-1 and IGFBP-3 appears to prolong the half-life and might counteract acute adverse events, particularly hypoglycemia associated with administration of IGF-1.
IGF-1 Binding (complex) of IGFBP-3 associated with hypoglycemia
8) Confidence 0.11 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2898102 Disease Relevance 1.12 Pain Relevance 0.21
IGF-I circulates as a ternary complex with IGFBP-3 and the acid-labile subunit, and both liver-derived proteins are under the control of GH [20].
IGF-I Binding (complex) of IGFBP-3 in liver
9) Confidence 0.11 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2206381 Disease Relevance 0.44 Pain Relevance 0.10
By complexing IGF-1 to its primary circulating binding protein IGFBP-3, it is possible to significantly increase the IGF-1 dose while eliminating the side effect of hypoglycemia that occurs with IGF-1 alone [101].
IGF-1 Binding (complexing) of protein IGFBP-3 associated with hypoglycemia
10) Confidence 0.02 Published 2009 Journal Osteoporos Int Section Body Doc Link PMC2832869 Disease Relevance 0.38 Pain Relevance 0
IGFBP-3 has a strong affinity for IGF-1 and, like IGFBP-5, can modulate its bioavailability and receptor binding - but in addition IGFBP-3 exhibits IGF-1-independent effects on MSCs [4,46].
IGF-1 Binding (affinity) of IGFBP-3 associated with bioavailability
11) Confidence 0.02 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875662 Disease Relevance 0.15 Pain Relevance 0.08
IGFBP-3 has a strong affinity for IGF-1 and, like IGFBP-5, can modulate its bioavailability and receptor binding - but in addition IGFBP-3 exhibits IGF-1-independent effects on MSCs [4,46].
IGF-1 Binding (affinity) of IGFBP-3 associated with bioavailability
12) Confidence 0.02 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875662 Disease Relevance 0.13 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox